AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

NeoImmuneTech to Present at the 2020 Biotech Showcase

January 3, 2020 GMT

ROCKVILLE, Md.--(BUSINESS WIRE)--Jan 3, 2020--

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced that it will present a company overview at the Biotech Showcase 2020 conference, taking place at the Hilton Union Square in San Francisco, CA.

NeoImmuneTech’s Chief Business Officer, Samuel Zhang, Ph.D., MBA, will review NeoImmuneTech’s recent progress and future directions, including an update on the company’s lead drug candidate, Hyleukin-7™. NeoImmuneTech is currently conducting several clinical trials of Hyleukin-7 in different types of cancer and multiple pre-IND and non-clinical studies in both solid tumors and hematologic malignancies.

Presentation details:
Date
: Tuesday, January 14
Time: 3:00pm PT
Track: Franciscan B (Ballroom Level)
Location: Hilton Hotel, Downtown San Francisco, CA

About Hyleukin-7™

Hyleukin-7™, the only clinical-stage long-acting human IL-7, is uniquely positioned to address unmet medical needs in immuno-oncology. IL-7 is a fundamental cytokine for T-cell development and for sustaining immune response to chronic antigens (as in cancer). Hyleukin-7′s favorable PK/PD and safety profiles make it an ideal combination partner for immunotherapy standard of care (SOC) such as Checkpoint Inhibitor and CAR-T therapies. Hyleukin-7 is being studied in multiple clinical trials in solid tumors, and is being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.

About NeoImmuneTech

NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the immuno-oncology frontier with Hyleukin-7 and beyond. NIT is partnering with industry and academic leaders to investigate Hyleukin-7 in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200103005008/en/

CONTACT: MacDougall

Shai Biran, Ph.D.

Direct: +1 781 235 3060

sbiran@macbiocom.com

KEYWORD: CALIFORNIA MARYLAND UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY

SOURCE: NeoImmuneTech, Inc.

Copyright Business Wire 2019.

PUB: 01/03/2020 07:00 AM/DISC: 01/03/2020 07:01 AM

http://www.businesswire.com/news/home/20200103005008/en